- KR₩42bn
- KR₩123bn
- KR₩75bn
- 38
- 51
- 29
- 30
Annual balance sheet for BCWorldPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS/A | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,561 | 4,503 | 8,058 | 11,166 | 7,911 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 14,722 | 15,942 | 17,778 | 19,483 | 20,914 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 43,063 | 37,235 | 43,609 | 48,086 | 44,558 |
| Net Property, Plant And Equipment | 125,500 | 132,370 | 130,119 | 125,628 | 120,985 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 176,925 | 179,358 | 183,051 | 184,111 | 176,313 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 56,160 | 55,892 | 84,206 | 92,246 | 85,865 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 92,764 | 97,901 | 103,499 | 102,468 | 99,645 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 84,161 | 81,458 | 79,552 | 81,643 | 76,668 |
| Total Liabilities & Shareholders' Equity | 176,925 | 179,358 | 183,051 | 184,111 | 176,313 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |